AcquisitionOther
Pfizer Inc. acquired Metsera, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Pfizer Inc. -> Metsera, Inc. · $4.9 billion enterprise value plus up to $22.50 per share in contingent payments
To add four highly differentiated clinical-stage incretin and amylin programs for obesity and cardiometabolic diseases.
Open source record (SEC) ↗